Blocking interleukin 33 reduces joint, systemic, and lung inflammatory responses in the combined collagen-induced arthritis-inhalant endotoxin exposure model.
Saved in:
| Title: | Blocking interleukin 33 reduces joint, systemic, and lung inflammatory responses in the combined collagen-induced arthritis-inhalant endotoxin exposure model. |
|---|---|
| Authors: | Poole JA; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: japoole@unmc.edu., Larsen JL; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Thiele GM; Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, Nebraska., Wyatt TA; Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, Nebraska; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Department of Environmental, Agricultural and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska., Nelson AJ; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Duryee MJ; Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, Nebraska., Gleason AM; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Schanze OW; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Schwab AD; Division of Allergy and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Dickinson JD; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Mosley D; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska., Lush M; Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska., Wang HJ; Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska., Cohen ES; Bioscience Asthma, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., England BR; Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, Nebraska., Mikuls TR; Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Veterans Affairs Nebraska-Western Iowa Health Care System, Research Service, Omaha, Nebraska. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2026 Jul 09, pp. 104983. Date of Electronic Publication: 2026 Jul 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
